All In Biotech

Drug Trial Radar · NCT06946225

ACTengine® IMA203 Combined With mRNA-4203

A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma or Synovial Sarcoma Patients (ACTengine® IMA203-102)

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jul 25, 2025

Primary completion

Aug 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Immatics US, Inc.Industry
Sponsor type
Industry
Collaborators
ModernaTX, Inc.
First posted
Apr 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).

Conditions

  • Cutaneous Melanoma
  • Synovial Sarcoma

Interventions

  • IMA203Biological

    Following non-myeloablative chemotherapy for lymphodepletion (LD) with fludarabine (FLU) and cyclophosphamide (CY), participants will receive a single infusion of IMA203 on Day 1 and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion.

  • mRNA-4203Biological

    mRNA-4203 will be administered starting on Day 15 after IMA203 infusion at the earliest. mRNA-4203 will be given for 12 cycles (28 day cycle length); during Cycle 1 it will be given on Day 1 and Day 15 and in Cycles 2-12 it will be given on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities (DLTs)Time frame: one year post infusion of IMA203
  2. Number of treatment emergent adverse events (AEs), AEs of special interest, serious AEs (SAEs), changes in laboratory parameters and vital signs, and frequency of dose interruptions, reductions and discontinuationsTime frame: one year post infusion of IMA203

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.